| scholarly article | Q13442814 |
| P50 | author | Casey S. Greene | Q41047284 |
| Benjamin F. Voight | Q56864510 | ||
| P2860 | cites work | A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline | Q22251083 |
| FTO Obesity Variant Circuitry and Adipocyte Browning in Humans | Q22305008 | ||
| DrugBank: a comprehensive resource for in silico drug discovery and exploration | Q24188653 | ||
| Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders | Q24558589 | ||
| The NHGRI GWAS Catalog, a curated resource of SNP-trait associations | Q24568334 | ||
| A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity | Q24650037 | ||
| Mutations in PCSK9 cause autosomal dominant hypercholesterolemia | Q28202519 | ||
| Obesity-associated variants within FTO form long-range functional connections with IRX3 | Q28236283 | ||
| A genome-wide association study identifies novel risk loci for type 2 diabetes | Q28287727 | ||
| Variation in FTO contributes to childhood obesity and severe adult obesity | Q28301922 | ||
| Use of genome-wide association studies for cancer research and drug repositioning | Q28544942 | ||
| Network-based in silico drug efficacy screening | Q28601372 | ||
| A gene-based association method for mapping traits using reference transcriptome data | Q28608356 | ||
| Genetics of rheumatoid arthritis contributes to biology and drug discovery | Q29417000 | ||
| Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits | Q29614593 | ||
| Sequence variations in PCSK9, low LDL, and protection against coronary heart disease | Q29616310 | ||
| Loss-of-function mutations in APOC3, triglycerides, and coronary disease | Q30408720 | ||
| Heterogeneous Network Edge Prediction: A Data Integration Approach to Prioritize Disease-Associated Genes | Q30979471 | ||
| Loss-of-function mutations in SLC30A8 protect against type 2 diabetes | Q33734046 | ||
| PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations | Q33808357 | ||
| Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans | Q33846034 | ||
| The Gene Ontology: enhancements for 2011 | Q34234620 | ||
| Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. | Q34385127 | ||
| Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis | Q34473809 | ||
| Phenome-wide association study (PheWAS) for detection of pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network | Q34574903 | ||
| Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data | Q35052005 | ||
| Inactivating mutations in NPC1L1 and protection from coronary heart disease | Q35105445 | ||
| Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery | Q35631111 | ||
| The support of human genetic evidence for approved drug indications | Q35677036 | ||
| International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways | Q36087896 | ||
| Network-based analysis of genetic variants associated with hippocampal volume in Alzheimer's disease: a study of ADNI cohorts | Q36476089 | ||
| Understanding multicellular function and disease with human tissue-specific networks | Q36790036 | ||
| VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies | Q36953937 | ||
| Enhancer-promoter interactions are encoded by complex genomic signatures on looping chromatin | Q37013090 | ||
| Genetic Association-Guided Analysis of Gene Networks for the Study of Complex Traits | Q38812107 | ||
| Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial | Q39091664 | ||
| VEGAS2: Software for More Flexible Gene-Based Testing | Q41677741 | ||
| DGIdb: mining the druggable genome | Q41917589 | ||
| Opportunities for drug repositioning from phenome-wide association studies. | Q44309573 | ||
| Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con | Q54508706 | ||
| Use of genome-wide association studies for drug repositioning | Q57338671 | ||
| FORGE: multivariate calculation of gene-wide p-values from Genome-Wide Association Studies Authors and Affiliations | Q57842424 | ||
| P433 | issue | R2 | |
| P304 | page(s) | R94-R98 | |
| P577 | publication date | 2016-06-23 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Human Molecular Genetics | Q2720965 |
| P1476 | title | Pathway and network-based strategies to translate genetic discoveries into effective therapies. | |
| P478 | volume | 25 |
Search more.